Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | PDE5A | O76074 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610940 | 0.88 | GBA1 (0.78) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL7612114 | 0.88 | GBA1 (0.78) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL7605588 | 0.86 | GBA1 (0.75) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL7610689 | 0.86 | GBA1 (0.75) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL16404321 | 0.84 | MAPK1 (0.82) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL17800023 | 0.84 | GBA1 (0.72) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL7287132 | 0.83 | KMT2A (1.00) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL17800064 | 0.81 | GBA1 (0.69) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL30125338 | 0.80 | GBA1 (0.66) | GBA1ALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL23723476 | 0.80 | GBA1 (0.66) | GBA1ALDH1A1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | GBA1 1282/4885ALDH1A1 1908/4885KDM4E 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.